NDV-3A

BIOLOGICAL3 trials

Sponsors

NovaDigm Therapeutics, Inc., National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

Autosomal-dominant Hyper-IgE SyndromeStaphylococcus AureusVulvovaginal Candidiasis

Phase 1

Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis

CompletedNCT01926028

NovaDigm Therapeutics, Inc.Vulvovaginal Candidiasis

Start: 2013-07-31End: 2016-05-31Updated: 2018-07-18

Phase 2

Safety, Tolerability, and Immunogenicity of One Dose of NDV 3A Vaccine in People With STAT3-Mutated Hyper-IgE Syndrome

TerminatedNCT02996448

National Institute of Allergy and Infectious Diseases (NIAID)Autosomal-dominant Hyper-IgE Syndrome

Start: 2016-11-17End: 2018-10-09Updated: 2020-06-30

Evaluation of NDV-3A Vaccine in Preventing S. Aureus Colonization

CompletedNCT03455309

NovaDigm Therapeutics, Inc.Staphylococcus Aureus

Start: 2018-01-30End: 2019-10-15Updated: 2020-01-29

Related Papers

A Fungal Immunotherapeutic Vaccine (NDV-3A) for Treatment of Recurrent Vulvovaginal Candidiasis—A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial

Clinical Infectious Diseases2018-03-01192 citations